Drugs / vYF vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07103148 Comparator | Jul 2025 → Aug 2026 overdue | yellow fever | Sanofi | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vYF vaccine | “vYF vaccine” NCT07103148 ↗ |
| Known as | vYF | “Eligible participants will be randomized in 2 independent groups (9-24 months, 2-5 years) to receive 1 dose of either vYF or Stamaril or YF-VAX in a 2:1:1 ratio within each age group.” NCT07103148 ↗ |
| Modality | Vaccine | “vYF (investigational vaccine)” NCT07103148 ↗ |